Forteo ® (teriparatide [rDNA origin] injection)

20-mcg daily dose in a 2.4-mL prefilled delivery device

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Approval and indications and Use of FORTEO® (teriparatide [rDNA origin] injection)

FORTEO® (teriparatide) is indicated for osteoporosis treatment in PMW, increased bone mass in men with primary or hypogonadal osteoporosis, and GIO.

See important safety information, including boxed warning, in the attached prescribing information. 



FORTEO® (teriparatide) was approved by the FDA on November 26, 2002.

Teriparatide is indicated for

  • the treatment of postmenopausal women with osteoporosis at high risk for fracture

  • increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, and

  • treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture (Forteo Package Insert, 2012).



Regarding teriparatide’s indication for treatment of post menopausal women with osteoporosis at high risk for fracture, high risk for fracture is defined as

  • a history of osteoporotic fracture

  • multiple risk factors for fracture, or

  • patients who have failed or are intolerant to other available osteoporosis therapy (Forteo Package Insert, 2012).

In postmenopausal women with osteoporosis, teriparatide reduces the risk of vertebral and nonvertebral fractures (Forteo Package Insert, 2012).

Reference

FORTEO [package insert]. Indianapolis, IN: Eli Lilly and Company; 2012.



Date of Last Review: September 13, 2017

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 8pm ET

Or you can

Ask us a question Chat with us

Submit a Request

Visit Us @LillyMedical